MIND MEDICINE (MINDMED) INC. Financials Mind Medicine (MindMed) Inc. Deutsche Boerse AG
Equities
MMQ
CA60255C8850
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.025 EUR | +2.62% |
|
-9.87% | +134.78% |
| May. 13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
| May. 08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,449 | 590.2 | 82.66 | 146.7 | 610.2 | - | - |
| Enterprise Value (EV) 1 | 3,368 | 456.6 | -59.49 | 61.17 | 425.3 | 510 | 403.5 |
| P/E ratio | -30.5 x | -6 x | -1.2 x | -1.5 x | -4.64 x | -5.93 x | -6.07 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | -106 x | -5 x | 0.94 x | -0.67 x | -4.82 x | -5.12 x | -3.63 x |
| EV / FCF | -139 x | -9.97 x | 1.19 x | -0.95 x | -6.1 x | -5.93 x | -3.34 x |
| FCF Yield | -0.72% | -10% | 84.3% | -105% | -16.4% | -16.9% | -29.9% |
| Price to Book | - | - | - | 1.83 x | 4.16 x | 9.13 x | 4.1 x |
| Nbr of stocks (in thousands) | 75,377 | 28,511 | 37,571 | 40,095 | 71,872 | - | - |
| Reference price 2 | 45.75 | 20.70 | 2.200 | 3.660 | 8.490 | 8.490 | 8.490 |
| Announcement Date | 3/30/21 | 3/28/22 | 3/9/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | -31.89 | -91.24 | -63.15 | -90.7 | -88.25 | -99.7 | -111 |
| EBIT 1 | - | - | -93.85 | -66.33 | -93.87 | -94.73 | -110.7 | -131.5 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -35.34 | -94.19 | -56.8 | -95.73 | -123.4 | -104.6 | -118.3 |
| Net income 1 | -5.474 | -35.34 | -93.04 | -56.8 | -95.73 | -123 | -105.9 | -120.5 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -0.7500 | -1.500 | -3.450 | -1.840 | -2.440 | -1.828 | -1.432 | -1.398 |
| Free Cash Flow 1 | - | -24.18 | -45.82 | -50.14 | -64.36 | -69.75 | -86.05 | -120.8 |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/30/21 | 3/28/22 | 3/9/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -24.29 | -17.72 | -16.12 | -16.19 | -13.11 | -20.07 | -28.39 | -20.82 | -21.42 | - | -20.6 | -21.9 | -24.1 | - | - |
| EBIT 1 | -19.2 | -18.5 | -16.94 | -16.98 | -13.9 | -20.86 | -29.18 | -21.62 | -22.2 | -22.2 | -22.8 | -23.88 | -25.77 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -19.9 | -18.45 | -16.96 | -16.48 | -4.903 | -24.82 | -29.13 | -17.92 | -23.86 | -54.4 | -21.71 | -22.55 | -24.12 | - | - |
| Net income 1 | -18.75 | -18.45 | -16.96 | -16.48 | -4.903 | -24.82 | -29.13 | -17.92 | -23.86 | -54.4 | -21.27 | -22.04 | -24.97 | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.7500 | -0.6000 | -0.6000 | -0.5600 | -0.0200 | -0.6500 | -0.7600 | -0.4500 | -0.5900 | -1.140 | -0.3000 | -0.3083 | -0.3483 | -0.3600 | -0.3600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/16/22 | 8/11/22 | 11/10/22 | 3/9/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/28/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 80.1 | 134 | 142 | 85.6 | 185 | 100 | 207 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -24.2 | -45.8 | -50.1 | -64.4 | -69.8 | -86.1 | -121 |
| ROE (net income / shareholders' equity) | - | - | - | - | -83.6% | -107% | -92.8% | -90.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | 2.000 | 2.040 | 0.9300 | 2.070 |
| Cash Flow per Share 2 | - | - | - | - | -1.640 | -0.8900 | -1.030 | -0.9800 |
| Capex 1 | - | - | - | - | - | 3 | 10 | 12.5 |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/30/21 | 3/28/22 | 3/9/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.49
USD
Average target price
23.86
USD
Spread / Average Target
+181.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +48.60% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- MNMD Stock
- MMQ Stock
- Financials Mind Medicine (MindMed) Inc.
